Payment overview · 2025
General Payments
$2,314.05
125 reported records · 27 companies
Healthcare provider profile · identity verified
Curtis M Healey, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH OGDEN, UT · NPI 1922021427
Verified facts
What the public records show
CMS Open Payments records show Curtis M Healey, MD received $2,314.05 in general payments during 2025 across 125 reported records.
Amgen Inc. accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $331.35 | 14.3% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $210.75 | 9.1% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $174.79 | 7.5% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.67 | 7.2% | 10 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $158.88 | 6.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.71 | 6.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.98 | 6.4% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $143.95 | 6.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.99 | 5.9% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $104.37 | 4.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.51 | 4.3% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.70 | 3.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.64 | 2.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.46 | 2.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.00 | 2.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.12 | 1.4% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $32.61 | 1.4% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $26.60 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $25.02 | 1.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.28 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.34 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.87 | 0.7% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.55 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.52 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.57 | 0.6% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $14.46 | 0.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.36 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,314.05 | 125 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $210.75 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $199.33 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $168.25 | 9 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $160.91 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $158.88 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $156.17 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $143.95 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $132.02 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $132.02 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.45 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $112.17 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.15 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $102.46 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.70 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.35 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.68 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.85 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.64 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.83 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.02 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $11.50 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $11.50 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $11.50 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 105 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 101 |
| Omeprazole | Omeprazole | 337 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 82 |
| Gabapentin | Gabapentin | 209 | 62 |
| Losartan Potassium | Losartan Potassium | 209 | 60 |
| Lisinopril | Lisinopril | 207 | 67 |
| Celecoxib | Celecoxib | 187 | 65 |
| Tramadol Hcl | Tramadol Hcl | 173 | 48 |
| Famotidine | Famotidine | 159 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 41 |
| Meloxicam | Meloxicam | 153 | 52 |
| Metformin Hcl | Metformin Hcl | 144 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 33 |
| Farxiga | Dapagliflozin Propanediol | 111 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 33 |
| Eliquis | Apixaban | 105 | 24 |
| Sertraline Hcl | Sertraline Hcl | 104 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 21 |
| Metformin Hcl Er | Metformin Hcl | 98 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 33 |
| Furosemide | Furosemide | 93 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 26 |
| Potassium Chloride | Potassium Chloride | 82 | 28 |
| Pregabalin | Pregabalin | 80 | 18 |
| Trazodone Hcl | Trazodone Hcl | 80 | 21 |
| Irbesartan | Irbesartan | 76 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 16 |
| Alprazolam | Alprazolam | 72 | 14 |
| Carvedilol | Carvedilol | 72 | 25 |
| Myrbetriq | Mirabegron | 68 | 20 |
| Donepezil Hcl | Donepezil Hcl | 64 | 21 |
| Bupropion Xl | Bupropion Hcl | 63 | 20 |
| Xarelto | Rivaroxaban | 63 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 18 |
| Methocarbamol | Methocarbamol | 55 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 12 |
| Jardiance | Empagliflozin | 51 | 13 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Ezetimibe | Ezetimibe | 50 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 15 |
| Glimepiride | Glimepiride | 49 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 21 |
| Simvastatin | Simvastatin | 48 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 48 | 15 |
| Montelukast Sodium | Montelukast Sodium | 47 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 16 |
| Topiramate | Topiramate | 44 | 11 |
| Allopurinol | Allopurinol | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Lamotrigine | Lamotrigine | 42 | 11 |
| Estradiol | Estradiol | 40 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Finasteride | Finasteride | 37 | 11 |
| Valsartan | Valsartan | 37 | 11 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | 11 |
| Cefdinir | Cefdinir | 33 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 13 |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Fluconazole | Fluconazole | 17 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,314.05 · 125 records | Amgen Inc. | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, Heplisav-B, INSPIRE, JARDIANCE, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error